ACKR1 | Atypical chemokine receptor 1 (Duffy blood group) | Blood group antigen proteins CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
ACKR2 | Atypical chemokine receptor 2 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
AGTR1 | Angiotensin II receptor, type 1 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Group enriched |
AQP2 | Aquaporin 2 (collecting duct) | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
ATP6V0A1 | ATPase, H+ transporting, lysosomal V0 subunit a1 | Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ATP7B | ATPase, Cu++ transporting, beta polypeptide | Cancer-related genes Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
CASR | Calcium-sensing receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CCR6 | Chemokine (C-C motif) receptor 6 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CCR7 | Chemokine (C-C motif) receptor 7 | Cancer-related genes CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CD97 | CD97 molecule | CD markers G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Expressed in all |
CHRM1 | Cholinergic receptor, muscarinic 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CXCR2 | Chemokine (C-X-C motif) receptor 2 | Cancer-related genes CD markers G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CXCR3 | Chemokine (C-X-C motif) receptor 3 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CXCR5 | Chemokine (C-X-C motif) receptor 5 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CYBB | Cytochrome b-245, beta polypeptide | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
DRD5 | Dopamine receptor D5 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
EDNRA | Endothelin receptor type A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
ELOVL3 | ELOVL fatty acid elongase 3 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
ELOVL5 | ELOVL fatty acid elongase 5 | Enzymes Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
ELTD1 | EGF, latrophilin and seven transmembrane domain containing 1 | G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | | | | Mixed |
FAIM2 | Fas apoptotic inhibitory molecule 2 | Predicted membrane proteins
| | | | | Tissue enriched |
GABBR2 | Gamma-aminobutyric acid (GABA) B receptor, 2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enriched |
GLP2R | Glucagon-like peptide 2 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR113 | G protein-coupled receptor 113 | G-protein coupled receptors Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
GPR123 | G protein-coupled receptor 123 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR132 | G protein-coupled receptor 132 | G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
GPR135 | G protein-coupled receptor 135 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR160 | G protein-coupled receptor 160 | G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
GPR162 | G protein-coupled receptor 162 | G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GPR182 | G protein-coupled receptor 182 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
GPR61 | G protein-coupled receptor 61 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
HAS3 | Hyaluronan synthase 3 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
HCRTR2 | Hypocretin (orexin) receptor 2 | G-protein coupled receptors Predicted membrane proteins
| | | | | Not detected |
HTR2A | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
HTT | Huntingtin | Disease related genes Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
ITPR1 | Inositol 1,4,5-trisphosphate receptor, type 1 | Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
MBTPS2 | Membrane-bound transcription factor peptidase, site 2 | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Expressed in all |
MLC1 | Megalencephalic leukoencephalopathy with subcortical cysts 1 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
NPSR1 | Neuropeptide S receptor 1 | Disease related genes G-protein coupled receptors Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
OPRM1 | Opioid receptor, mu 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
P2RY12 | Purinergic receptor P2Y, G-protein coupled, 12 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
P2RY13 | Purinergic receptor P2Y, G-protein coupled, 13 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
PSEN1 | Presenilin 1 | Cancer-related genes Disease related genes Enzymes Potential drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
PTCHD3 | Patched domain containing 3 | Predicted membrane proteins
| | | | | Tissue enriched |
RYR1 | Ryanodine receptor 1 (skeletal) | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC13A3 | Solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC1A6 | Solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6 | Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
SLC4A1 | Solute carrier family 4 (anion exchanger), member 1 (Diego blood group) | Blood group antigen proteins CD markers Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC7A8 | Solute carrier family 7 (amino acid transporter light chain, L system), member 8 | Predicted membrane proteins Transporters
| | | | | Expressed in all |